logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > Chemical Intermediates > R-(+)-Lansoprazole CAS 138530-94-6

R-(+)-Lansoprazole CAS 138530-94-6

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 138530-94-6

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Bag,Drum

Delivery Time: 7-15 days

Payment Terms: L/C, D/A, T/T, Western Union

Supply Ability: TON

Get Best Price
Highlight:
CAS NO::
138530-94-6
Appearance::
Brown Solid
Molecular Formula::
C16H14F3N3O2S
Molecular Weight::
369.36100
EINECS NO::
NA
MDL NO::
MFCD13196699
CAS NO::
138530-94-6
Appearance::
Brown Solid
Molecular Formula::
C16H14F3N3O2S
Molecular Weight::
369.36100
EINECS NO::
NA
MDL NO::
MFCD13196699
R-(+)-Lansoprazole CAS 138530-94-6

Product Description:

Product Name: R-(+)-Lansoprazole CAS NO: 138530-94-6

 

 

Synonyms:

(R)-2-(3-N,N-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenoxyisobutyrate;

FESO;

R-lansoprazole;

 

 

Chemical & Physical Properties:

Appearance: Brown solid

Assay :≥99.00%

Density: 1.50±0.1 g/cm3(Predicted)

Melting Point: 66-68℃

Boiling Point: 555.8±60.0℃(Predicted)

Storage temp.: Refrigerator

Vapour Pressure: 0.0±1.5 mmHg at 25℃

Index of Refraction: 1.635

 

 

(R)-Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid.Target: Proton PumpLansoprazole sodium is sodium salt form of lansoprazole, lansoprazole, a substituted benzimidizole proton pump inhibitor, on pharmacokinetics and metabolism of theophylline has been studied in healthy adults given oral lansoprazole 30 mg once daily for 11 days. On Days 4 and 11 of 300 mg aminophylline was simultaneously administered orally and blood samples for theophylline analysis were taken over 24 h. Patients in the lansoprazole group were significantly less likely to have a recurrence of ulcer complications than patients in the placebo group (P=0.008). There was no significant difference in mortality between the two groups. lansoprazole (AG-1749) and omeprazole, were found to have significant activities against this organism. The activity of lansoprazole was comparable to that of bismuth citrate, with MICs ranging from 3.13 to 12.5 micrograms/ml, and fourfold more potent than that of omeprazole. 

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.